IP Library › Granted Patent US 12,624,085
Granted Patent B2
US 12,624,085 · App. 17/255,108 · Granted May 12, 2026

Compositions and methods of NKG2D chimeric antigen receptor T cells for controlling triple-negative breast cancer

Inventors: Daniel Powell (Bala Cynwyd, PA); De-Gang Song (Philadelphia, PA)
Assignee: The Trustees of the University of Pennsylvania
C07K14/7056A61K40/11A61K40/31A61K40/4202A61K40/4224A61K45/06A61P35/00C07K14/7051C07K14/70517C07K14/70578C12N5/0636A61K2239/10A61K2239/15A61K2239/17A61K2239/21A61K2239/22A61K2239/31A61K2239/38A61K2239/49C07K2319/00C07K2319/03C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,624,085
App. No.
17/255,108
Granted
May 12, 2026
Kind
B2
Abstract

The invention includes a chimeric antigen receptor (CAR) specific for a natural-killer group 2, member D ligand (NKG2DL), compositions comprising the CAR, polynucleotides encoding the CAR, vectors comprising a polynucleotide encoding the CAR, and recombinant T cells comprising the CAR. The invention also includes methods of making a genetically modified T cell expressing a NKG2D-CAR wherein the expressed CAR comprises a NKG2D extracellular domain. The present invention also relates generally to the use of T cells engineered to express a CAR to treat cancer associated with NKG2D.

Claims (21)

1 . A nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the nucleic acid molecule comprises a nucleic acid sequence encoding a natural-killer group 2, member D (NKG2D) extracellular domain, a nucleic acid sequence encoding a CD27 costimulatory domain, and a nucleic acid sequence encoding a CD3 zeta signaling domain,

wherein the CAR comprises, from amino to carboxy terminus, the NKG2D extracellular domain, the CD27 costimulatory domain, and the CD3 zeta signaling domain, and

wherein the CAR comprises the amino acid sequence of SEQ ID NO: 15.

2 . The nucleic acid molecule of claim 1 , wherein the nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO: 14.

3 . A vector comprising the nucleic acid molecule of claim 1 .

4 . A chimeric antigen receptor (CAR) comprising a natural-killer group 2, member D (NKG2D) extracellular domain, a CD27 costimulatory domain, and a CD3 zeta signaling domain,

wherein the CAR comprises, from amino to carboxy terminus, the NKG2D extracellular domain, the CD27 costimulatory domain, and the CD3 zeta signaling domain, and

wherein the CAR comprises the amino acid sequence of SEQ ID NO: 15.

5 . The CAR of claim 4 , wherein the CAR is encoded by the nucleic acid sequence of SEQ ID NO: 14.

6 . A genetically modified T cell comprising the CAR of claim 4 .

7 . A method for treating cancer in a subject, the method comprising: administering to the subject an effective amount of the genetically modified T cell of claim 6 , thereby treating cancer in the subject.

8 . A genetically modified T cell comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the nucleic acid molecule comprises a nucleic acid sequence encoding, from amino to carboxy terminus, a natural-killer group 2, member D (NKG2D) extracellular domain, a nucleic acid sequence encoding a CD27 costimulatory domain, and a nucleic acid sequence encoding a CD3 zeta signaling domain,

wherein the CAR comprises the amino acid sequence of SEQ ID NO: 15 or is encoded by the nucleic acid sequence of SEQ ID NO: 14.

9 . A genetically modified T cell comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO: 16 or encodes the amino acid sequence of SEQ ID NO: 17.

10 . A genetically modified T cell comprising a chimeric antigen receptor (CAR), wherein the CAR comprises the amino acid sequence of SEQ ID NO: 19 or is encoded by the nucleic acid sequence of SEQ ID NO: 18.

11 . A vector comprising a nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the nucleic acid molecule comprises a nucleic acid sequence encoding, from amino to carboxy terminus, a natural-killer group 2, member D (NKG2D) extracellular domain, a nucleic acid sequence encoding a CD27 costimulatory domain, and a nucleic acid sequence encoding a CD3 zeta signaling domain,

wherein the nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO: 1.

12 . A method for treating triple negative breast cancer (TNBC) in a subject, the method comprising: administering to the subject an effective amount of a genetically modified T cell comprising a nucleic acid molecule encoding, from amino to carboxy terminus, a chimeric antigen receptor (CAR), wherein the nucleic acid molecule comprises a nucleic acid sequence of a natural-killer group 2, member D (NKG2D) extracellular domain, a nucleic acid sequence encoding a CD27 costimulatory domain, and a nucleic acid sequence encoding a CD3 zeta signaling domain, thereby treating TNBC in the subject.

13 . The method of claim 12 , wherein the subject is a human.

14 . The method of claim 12 , further comprising wherein the subject is administered a secondary treatment.

15 . The method of claim 14 , wherein the secondary treatment is selected from the group consisting of immune checkpoint blockade, chemotherapy, radiation, and surgery.

Continuity (2)
Provisional Application 62689552 · Jun 25, 2018
Related Publication 20210269501A1 · Sep 2, 2021
References Cited (32)
US 7994298B2 · Zhang · 2011 [cited by applicant]
US 8252914B2 · Zhang · 2012 [cited by applicant]
US 9573988B2 · Brogdon · 2017 [cited by examiner]
US 20130266551A1 · Campana · 2013 [cited by examiner]
US 20140050708A1 · Powell · 2014 [cited by applicant]
US 20140286973A1 · Powell, Jr. · 2014 [cited by applicant]
US 20150225480A1 · Powell, Jr. · 2015 [cited by applicant]
US 20160000828A1 · Campana · 2016 [cited by applicant]
US 20200131244A1 · Leong · 2020 [cited by examiner]
WO WO2018165913A1 · 2018 [cited by examiner]
Song, De-Gang, et al. “CD27 Costimulation Augments the Survival and Antitumor Activity of Redirected Human T Cells in Vivo.” Blood, vol. 119, No. 3, Jan. 19, 2012, pp. 696-706, https://doi.org/10.1182/blood-2011-03-3442… [cited by examiner]
Agaugue et al. The high expression of NKG2D ligands on tumor and the lack of surface expression on healthy tissues provides a strong rationale to support NKG2D-based therapeutic approaches for cancer. Immunother Cancer … [cited by examiner]
Dhar et al. NKG2D and its ligands in cancer. Curr Opin Immunol 51: 55-61, 2018. [cited by examiner]
WO 2018165913 English language translation (20 total pages). [cited by examiner]
Barber et al. J Immunol 2008; 180:72-78. [cited by applicant]
Barber, A., et al., Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer research, 2007. 67(10): p. 5003-5008. [cited by applicant]
Barber, A., et al., Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma. Experimental hematology, 2008. 36(10): p. 1318-1328. [cited by applicant]
De Kruijf, E.M., et al., NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. Bmc Cancer, 2012. 12(1): p. 24. [cited by applicant]
International Search Report and Written Opinion issued Nov. 20, 2019 in International Application No. PCT/US2019/038739. [cited by applicant]
Kalos Michael et al, “T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia”, Aug. 10, 2011, (Aug. 10, 2011), vol. 3, No. 95, p. 95ra73.1, XP00… [cited by applicant]
Kershaw et al, Gene-engineered T cells for cancer therapy, Nature, 2013, pp. 525-541. [cited by applicant]
Kim et al., Journal of Immunotherapy. 2008; 31(5):475-486. [cited by applicant]
Lehner, M., et al., Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PloS one, 2012. 7(2): p. e31210. [cited by applicant]
Lynn, R.C. and D.J. Powell, Strain-dependent lethal toxicity in NKG2D ligand-targeted CAR T-cell therapy. Molecular Therapy, 2015. 23(10): p. 1559-1561. [cited by applicant]
Nausch, N. and A. Cerwenka, NKG2D ligands in tumor immunity. Oncogene, 2008. 27(45): p. 5944-5958. [cited by applicant]
Nikiforow, S., et al., Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma. 2016, Am Soc Hematology. [cited by applicant]
Song D-G et al., Human gene therapy. 2013; 24(3):295-305. [cited by applicant]
Song, D.G., et al., “In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)”, Cancer Res 71, 4617-4627 (2011). [cited by applicant]
Song, et al., “CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.”, Blood 119:, 696-706, 2012. [cited by applicant]
VanSeggelen, H., et al., T cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice. Molecular Therapy, 2015. 23(10): p. 1600-1610. [cited by applicant]
Zhang et al. “Generation of Antitumor Responses by Genetic Modification of Primary Human T Cells with a Chimeric NKG2D Receptor” Cancer Research (2006) vol. 66, No. 11, pp. 5927-5933. [cited by applicant]
Zhang, T., B.A. Lemoi, and C.L. Sentman, Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood, 2005. 106(5): p. 1544-1551. [cited by applicant]